Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States

Overview of attention for article published in BMC Cancer, March 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 17 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 906 followers.

New article: Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States https://t.co/RHlloHyyDT #prostatecancer #oncology https://t.co/gF8uCrgJS9

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.